Software license allocations to Kyiv-based Meta Bureau LLC could yield up to $13.2 million for Swarmer if all contract options are exercised TALLINN, Estonia, May 13, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc. (“Swarmer” or the “Company”) (NASDAQ: SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced that Meta Bureau LLC awarded its subsidiary, Swarmer Estonia OÜ, a contract with an initial value of $2.86 million for more than 16,000 software licenses to be used aboard its SkyKnight quadcopter bombers and other unmanned aerial vehicles (UAVs). The contract also allows Meta Bureau to elect to upgrade certain licenses for an additional $10.4 million. “Just like Meta Bureau, Swarmer’s technology is battle-proven and able to work together seamlessly...

– Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers – Phase 1 SAD and MAD data expected by year-end 2026 BEIJING, May 13, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in the Phase 1 trial of ICP-054 (ZB021), a novel potentially best-in-class oral IL-17AA/AF inhibitor. The Phase 1 trial is supported by robust preclinical data demonstrating a desirable pharmacology and toxicology profile. In addition to potent inhibition of IL-17AA/AF signaling, and anti-inflammatory activity demonstrated in preclinical animal models, excellent oral bioavailability was observed across...

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY Goldman Sachs 47th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FLA live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and...

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA granted Fast Track designation to imdusiran, which has the potential to facilitate development and accelerate FDA review WARMINSTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported first quarter 2026 financial results and provided a corporate update. LNP LitigationOn March 3, 2026, Arbutus, along with its exclusive licensee, Genevant Sciences (“Genevant”), entered into a settlement agreement to resolve all global patent infringement litigation...

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences:RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 19, 2026, fireside chat at 2:35 p.m. ET; andStifel Virtual Oncology Forum on Wednesday, May 20, 2026, fireside chat at 3:30 p.m. ET; andJefferies Global Healthcare Conference in New York, NY on Thursday, June 4, 2026, fireside chat at 7:35 a.m. ET.Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology,...

Redesigned platform delivers streamlined purchasing, improved system navigation, and expanded tools for both retail and B2B customersRENO, Nev., May 13, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and maker of Battle Born Batteries®, today announced the launch of its newly redesigned e-commerce website for the Battle Born brand. The new website is designed to make it easier for customers to find, understand, and purchase reliable lithium power solutions. Whether upgrading a single battery or building a complete system, users can more efficiently navigate products, explore options, and make informed decisions based on their specific application. “This launch is centered around the customer experience,” said Tyler Bourns, Chief...

– Three patients treated with ZEVASKYN® in Q1 2026 – – QTC network expands to six sites, with two new additions on the East Coast –  – In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized – – $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 – – Webcast today at 8:30am ET – CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2026, highlighting commercial momentum for ZEVASKYN.Steady increase in ZEVASKYN adoption with three patients completing treatment in the first quarter of 2026, one treatment to date in the second quarter, one biopsy currently in...

Revenue grew approximately 35% year-over-year to $15.5 million for Q1 2026 Net income increased by over 100% year-over-year to $2.3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year-over-year to $2.8 million  Remaining performance obligations grew 25% year-over-year to approximately $75 million Shipped a record total of 117 Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Reiterates full-year 2026 financial guidance, including revenue of $66 – $68 million, operating income of 13% – 14%, and Adjusted EBITDA of $12 – $14 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 13, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...

Initial Commercial Rollout Has Commenced with Three Franchisees in Three US States VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, improving food quality, minimizing waste and enhancing sustainability, today announced that it has commenced commercial sales with another medium-sized fast food chain in the United States. This achievement represents another major advancement in Beyond Oil’s U.S. commercial expansion strategy, following an extensive pilot validation program that began in late 2025 and expanded to a multi-location pilot in Q1 of 2026. The pilots demonstrated Beyond Oil’s exceptional performance under...